Collectively, these experiments demonstrate that the inactivation of PI3K–AKT-mTOR signaling induces ferroptosis via SREBP1/SCD1-mediated lipogenesis, and that TYM-3-98 is a promising therapeutic agent for the treatment of KRAS-mutated CRC cells. The gene discussed is AKT1; the disease is colorectal carcinoma.